FY2030 Earnings Forecast for CMPS Issued By HC Wainwright

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Compass Pathways in a research report issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of $6.46 per share for the year. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share.

Several other research analysts have also recently issued reports on CMPS. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Compass Point set a $15.00 price target on shares of Compass Pathways in a research report on Thursday, February 12th. Morgan Stanley boosted their price objective on shares of Compass Pathways from $11.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Royal Bank Of Canada upped their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Finally, Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Compass Pathways currently has an average rating of “Moderate Buy” and an average price target of $22.13.

Compass Pathways Price Performance

CMPS opened at $6.78 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The stock’s 50 day simple moving average is $6.98 and its 200 day simple moving average is $6.13. The firm has a market cap of $651.00 million, a price-to-earnings ratio of -2.49 and a beta of 1.90. Compass Pathways has a 1 year low of $2.25 and a 1 year high of $8.90.

Hedge Funds Weigh In On Compass Pathways

Several hedge funds and other institutional investors have recently modified their holdings of CMPS. Corient Private Wealth LLC raised its holdings in Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after buying an additional 1,200 shares during the last quarter. CWM LLC increased its position in shares of Compass Pathways by 19.2% during the third quarter. CWM LLC now owns 15,650 shares of the company’s stock valued at $90,000 after acquiring an additional 2,525 shares in the last quarter. Conservest Capital Advisors Inc. raised its holdings in Compass Pathways by 24.6% in the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after acquiring an additional 5,000 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in Compass Pathways in the 4th quarter worth approximately $38,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Compass Pathways by 46.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after acquiring an additional 5,817 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright substantially raised multi-year EPS forecasts (FY2026–FY2029/FY2030) and reiterated a “Buy” rating with a $70 price target, projecting a path from near-term losses to meaningful profitability in later years — a bullish research-note catalyst that can support higher valuation expectations. HC Wainwright Forecasts Strong Price Appreciation for Compass Pathways (NASDAQ:CMPS) Stock
• Neutral Sentiment: Short-interest reports in early March show “0 shares” and NaN changes with a reported days-to-cover of 0.0 — this appears to be a data anomaly and therefore provides little reliable information about bearish positioning or short-covering dynamics at present.
• Negative Sentiment: Despite HC Wainwright’s bullish revisions, the consensus earnings estimate remains negative (current-year consensus ~($2.33) EPS) and the company is not yet profitable. That gap between an upbeat outlier forecast and market consensus raises execution and timing risk; investors may be selling into the analyst headlines until clearer, near-term operational progress is visible.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.